Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Profit After Tax (2020 - 2023)

Candel Therapeutics' Profit After Tax history spans 4 years, with the latest figure at -$11.1 million for Q4 2023.

  • For Q4 2023, Profit After Tax fell 117.55% year-over-year to -$11.1 million; the TTM value through Dec 2023 reached -$37.9 million, down 101.8%, while the annual FY2024 figure was -$55.2 million, 45.44% down from the prior year.
  • Profit After Tax for Q4 2023 was -$11.1 million at Candel Therapeutics, down from -$8.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $1.6 million in Q4 2021 and bottomed at -$17.1 million in Q2 2021.
  • The 4-year median for Profit After Tax is -$6.1 million (2020), against an average of -$7.0 million.
  • The largest annual shift saw Profit After Tax soared 126.66% in 2021 before it tumbled 906.29% in 2023.
  • A 4-year view of Profit After Tax shows it stood at -$6.1 million in 2020, then skyrocketed by 126.66% to $1.6 million in 2021, then crashed by 414.81% to -$5.1 million in 2022, then tumbled by 117.55% to -$11.1 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Profit After Tax are -$11.1 million (Q4 2023), -$8.4 million (Q3 2023), and -$9.6 million (Q2 2023).